Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.53 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456428 | 0.89 | GAA (0.56) | SMN1; SMN2ALDH1A1CNR2KMT2AMAPT | |
| SCHEMBL5454223 | 0.86 | CNR2 (0.48) | SMN1; SMN2ALDH1A1CNR2KMT2ACNR1 | |
| SCHEMBL5418358 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A | |
| SCHEMBL5450086 | 0.83 | CNR2 (0.62) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A | |
| SCHEMBL5451254 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A | |
| SCHEMBL5453696 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A | |
| SCHEMBL5454706 | 0.82 | DRD3 (0.60) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A | |
| SCHEMBL5441631 | 0.82 | CNR2 (0.62) | SMN1; SMN2ALDH1A1CREBBPCNR2MAPT | |
| SCHEMBL5454647 | 0.81 | CNR2 (0.74) | SMN1; SMN2ALDH1A1CREBBPCNR2CNR1 | |
| SCHEMBL5448762 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1CREBBPCNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SMN1; SMN2 1701/4885ALDH1A1 2963/4885CREBBP 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.